A retrospective analysis of the PALOMA-2 trial, which randomized patients with HR+/HER2‒ advanced breast cancer to letrozole +/− palbociclib, analyzed the molecular subtype of 455 tumors. This evidence concerns the gene ERBB2 and breast carcinoma.